iCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed product candidates include iCo-008, a human monoclonal antibody, which is in Phase II clinical trial to treat sight threatening ocular allergies and various systemic disease indications; and Oral AmpB Delivery System that is in pre-clinical stage used for the treatment of systemic fungal infections. The company was founded in 2005 and is headquartered in Vancouver, Canada.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone778-802-9806
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date4/23/2019 (Estimated)
OptionableNot Optionable
iCo Therapeutics (OTCMKTS:ICOTF) Frequently Asked Questions
What is iCo Therapeutics' stock symbol?
iCo Therapeutics trades on the OTCMKTS under the ticker symbol "ICOTF."
When is iCo Therapeutics' next earnings date?
Has iCo Therapeutics been receiving favorable news coverage?
News stories about ICOTF stock have been trending very negative this week, InfoTrie reports. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. iCo Therapeutics earned a news impact score of -3.6 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near term.
Who are some of iCo Therapeutics' key competitors?
Some companies that are related to iCo Therapeutics include Aileron Therapeutics (ALRN), Novan (NOVN), ContraFect (CFRX), Q BioMed (QBIO), Adial Pharmaceuticals (ADIL), Heat Biologics (HTBX), Acerus Pharmaceuticals (TRLPF), Citius Pharmaceuticals (CTXR), Evoke Pharma (EVOK), IMMURON LTD/S (IMRN), SUMMIT THERAPEU/S (SMMT), RegeneRx Biopharmaceuticals (RGRX), Onconova Therapeutics (ONTX), MOTIF BIO PLC/S (MTFB) and Ceapro (CRPOF).
What other stocks do shareholders of iCo Therapeutics own?
Who are iCo Therapeutics' key executives?
iCo Therapeutics' management team includes the folowing people:
- Mr. Andrew J. Rae M.B.A., BSc, MBA, Co-Founder, CEO, Pres & Director (Age 52)
- Mr. Michael Liggett CPA, CA, Bsc. Pharm., CFO, Corp. Sec. & Director (Age 59)
- Dr. Peter Hnik M.D., MHSc, Chief Medical Officer (Age 63)
How do I buy shares of iCo Therapeutics?
Shares of ICOTF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is iCo Therapeutics' stock price today?
One share of ICOTF stock can currently be purchased for approximately $0.0627.
How big of a company is iCo Therapeutics?
iCo Therapeutics has a market capitalization of $6.86 million.
What is iCo Therapeutics' official website?
How can I contact iCo Therapeutics?
iCo Therapeutics' mailing address is 777 Hornby Street 6th Floor, Vancouver A1, V6Z 1S4. The biotechnology company can be reached via phone at 778-802-9806 or via email at [email protected]
MarketBeat Community Rating for iCo Therapeutics (OTCMKTS ICOTF)
MarketBeat's community ratings are surveys of what our community members think about iCo Therapeutics and other stocks. Vote "Outperform" if you believe ICOTF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICOTF will underperform the S&P 500 over the long term. You may vote once every thirty days.
